OPHTHALMIC DRUG DELIVERY SYSTEM AND METHOD

• US 20100119519A1
• Filed: 11/03/2009
• Published: 05/13/2010
• Est. Priority Date: 11/13/2008
• Status: Abandoned Application

• Current Assignee: Gholam A. Peyman
• Original Assignee: Gholam A. Peyman
• Inventors: Peyman, Gholam A.
• Application Number:
  US12/611,682
• Publication Number:
  US 20100119519A1
• Time in Patent Office: Days
• US Class Current: 424/141.100
• CPC Class Codes: A61F 2/14 Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
• CPC Class Codes: A61F 2/1694 Capsular bag spreaders therefor
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 31/365 Lactones
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants

Abstract

An ocular device comprising a delivery body configured for implanting within the capsular bag of a patient'"'"'s eye, the delivery body containing an ocular therapeutic agent, the delivery body having a permeable exterior surface for delivering the therapeutic agent when implanted in the patient'"'"'s eye.

Claims

1. An ocular device comprising a delivery body configured for implanting within the capsular bag of a patient'"'"'s eye, the delivery body containing an ocular therapeutic agent, the delivery body having a permeable exterior surface for delivering the therapeutic agent when implanted in the patient'"'"'s eye.

2. The device of claim 1 made from a synthetic polymer or organic material.

3. The device of claim 1 made from the lens capsule.

4. The device of claim 2 where the therapeutic agent is within the synthetic polymer.

5. The device of claim 2 wherein the therapeutic agent is on a surface of the device.

6. The device of claim 1 wherein the therapeutic agent is selected from the group consisting of steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics, anti-fungals, antioxidants, macrolides including but not limited to cyclosporine, tacrolimis, rapamycin, mycophenolic acid and their analogs, voclosporin, immunomodulatores, etanercept, infliximab, adalimumab, antibodies, antiproliferative agents, gene delivery agents, neuroprotective agents, anti-glaucoma agents, and combinations thereof.

9. A method of treating an eye of a patient using the delivery body of claim 1 implanted in the eye.

7. An ocular device comprising a capsular bag extracted from a patient'"'"'s eye after surgical lens removal, the capsular bag containing an ocular therapeutic agent, for slow release delivery of the therapeutic agent and simultaneous support of a capsule of the extracted lens when implanted back in the patient'"'"'s eye.

8. The device of claim 7 wherein the therapeutic agent is selected from the group consisting of steroids, non-steroidal anti-inflammatory drugs (NSAIDS), antibiotics, anti-fungals, antioxidants, macrolides including but not limited to cyclosporine, tacrolimis, rapamycin, mycophenolic acid and their analogs, voclosporin, immunomodulatores, etanercept, infliximab, adalimumab, antibodies, antiproliferative agents, gene delivery agents, neuroprotective agents, anti-glaucoma agents, and combinations thereof.